EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Immunometabolic Rewiring of Dendritic Cells to Overcome Glutamine‐Driven Immune Suppression in Colorectal Cancer

Bingjie Zhang, Renming Fan, Yongrui Hai, Ye Chen, Xintong Lu, Wenhui Wang, Jiarui Dou, Jiaxin Yan, Chang Su, Yue Chen, Le Yang, Minggao Zhao und 2 weitere

Advanced Science · 2026

DOI: 10.1002/advs.202513986 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2026. Verfasst von Bingjie Zhang und 13 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Cellular Metabolism and Precision Therapeutics, Institute of Medical Research, Northwestern Polytechnical University, Xi'an, 710072, Ch…. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Glutamine, Dendritic Cells. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Shenzhen Science and Technology Program, Shaanxi Youth Rising Stars in Science and Technology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The immunosuppressive tumor microenvironment imposes significant metabolic constraints that impair dendritic cell (DC) maturation and antigen presentation, ultimately undermining antitumor immunity. In colorectal cancer (CRC), elevated glutamine uptake by tumor cells depletes extracellular glutamine, thereby limiting DC functionality and disrupting T cell priming. While glutamine antagonists such as JHU083 inhibit tumor metabolism, they are insufficient to fully restore DC activity. Here, the development of T26, a bifunctional immunometabolic prodrug that links JHU083 with the STING agonist MSA‐2 via a cleavable amide bond, is reported, enabling synchronized intratumoral release and dual targeting of glutamine metabolism and innate immune activation. In murine CRC models, T26 restores DC maturation, promotes CD8⁺ T cell activation, and reprograms tumor cell‐derived extracellular vesicles to enhance antigen presentation and immune stimulation. Importantly, T26 significantly inhibits the growth and proliferation of CRC patient‐derived organoids, underscoring its translational potential in human CRC. Notably, T26 also demonstrates strong synergy with chemotherapy, immune checkpoint blockade, and anti‐angiogenic therapy, significantly improving tumor control without inducing systemic toxicity. These findings position T26 as a mechanistically integrated and translationally promising strategy to overcome glutamine‐driven immune suppression and enhance immunotherapy efficacy in CRC and other metabolically dysregulated malignancies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsGlutamineDendritic CellsAnimalsMiceHumansTumor MicroenvironmentCell Line, TumorMice, Inbred C57BL

Stichwörter der Autor:innen

STINGcolorectal cancerdendritic cellsextracellular vesiclesglutamineimmunotherapy

Substanzen

Glutamine

Autor:innen und Institutionen

  • Laboratory of Cellular Metabolism and Precision Therapeutics, Institute of Medical Research, Northwestern Polytechnical University, Xi'an, 710072, China.
  • Research & Development Institute of Northwestern Polytechnical University in Shenzhen, Shenzhen, 518057, China.
  • Department of Pharmacy, Tangdu Hospital, The Fourth Military Medical University, Xi'an, 710038, China.
  • Department of Colorectal Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.

ORCID-Profile: Gaofei Wei

Förderung

  • National Natural Science Foundation of China
  • Shenzhen Science and Technology Program
  • Shaanxi Youth Rising Stars in Science and Technology
  • State Key Laboratory of Neurology and Oncology Drug Development
  • Innovation Foundation for Doctor Dissertation of Northwestern Polytechnical University
  • Shenzhen Science and Technology Innovation Program

Zitieren

APA

Zhang, B., Fan, R., Hai, Y., Chen, Y., Lu, X., Wang, W., Dou, J., Yan, J., Su, C., Chen, Y., Yang, L., Zhao, M., Liang, L., & Wei, G. (2026). Immunometabolic Rewiring of Dendritic Cells to Overcome Glutamine‐Driven Immune Suppression in Colorectal Cancer. Advanced Science. https://doi.org/10.1002/advs.202513986

Vancouver

Zhang B, Fan R, Hai Y, Chen Y, Lu X, Wang W, et al. Immunometabolic Rewiring of Dendritic Cells to Overcome Glutamine‐Driven Immune Suppression in Colorectal Cancer. Advanced Science. 2026. doi:10.1002/advs.202513986

BibTeX
@article{Zhang2026,
  author = {Zhang, Bingjie and Fan, Renming and Hai, Yongrui and Chen, Ye and Lu, Xintong and Wang, Wenhui and Dou, Jiarui and Yan, Jiaxin and Su, Chang and Chen, Yue and Yang, Le and Zhao, Minggao and Liang, Lei and Wei, Gaofei},
  title = {Immunometabolic Rewiring of Dendritic Cells to Overcome Glutamine‐Driven Immune Suppression in Colorectal Cancer},
  journal = {Advanced Science},
  year = {2026},
  doi = {10.1002/advs.202513986}
}
Kostenlos starten →